Tag Archives: Gilead Sciences Inc.

Top Stories for Week of March 9, 2020

      No Comments on Top Stories for Week of March 9, 2020

COVID-19 Addenda: Trump signs $8.3 billion emergency spending package; Italy coronavirus deaths near 200; $2 billion needed to develop new vaccine; U of Washington has closed classrooms. President Donald Trump… Read more »

Top Stories for Week of March 2, 2020

As the situation worsens, Gilead begins two, late-stage studies to test drug for coronavirus. The coronavirus, or COVID-19, has infected more than 80,000 people in about three dozen countries since… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Kite snags deal with Dutch biotech Gadeta to advance brand new CAR T-cell treatment for solid tumors.

The News: Kite Pharma Inc. (El Segundo CA) reportedly will support Gadeta BV (Utrecht NLD) in the development of a new type of CAR T-cell therapy that could be more… Read more »

Gilead makes breakout M&A move; buys CAR-T wunderkind Kite Pharma for $12 billion.

The News: Gilead Sciences Inc. (Foster City CA) announced it would buy cancer-immune therapy company Kite Pharma Inc. (Santa Monica CA) for about $11.9 billion to bolster its hugely successful but… Read more »

Novartis gets FDA nod for breakthrough leukemia treatment Kymriah; with a cost of $450,000, who’s going to get it?

The News: Novartis AG (Basel CHE) has obtained approval from the US Food and Drug Administration (FDA) for its Kymriah (tisagenlecleucel or CTL019) to treat children and young adults with… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Gilead’s slog downward accelerates; CEO’s growth reassurances need action–now

The News: Gilead Sciences Inc. (Foster City CA) on Tuesday (February 7, 2017) said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to… Read more »